Galectin Therapeutics Inc (GALT)

May 29, 2026

GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill

May 29, 2026

May 28, 2026

Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock By Investing.com - Investing.com India

May 28, 2026

May 28, 2026

Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock - Investing.com

May 28, 2026

May 28, 2026

Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise - Stock Titan

May 28, 2026

May 27, 2026

Galectin Therapeutics (GALT) Unveils New Insights from NAVIGATE Trial at EASL 2026 - GuruFocus

May 27, 2026

May 27, 2026

GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical Development ContinuesPre-Earnings Setup - thelegaladvocate.com

May 27, 2026

May 27, 2026

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis - The Manila Times

May 27, 2026

May 22, 2026

Galectin Therapeutics (GALT) Holds Near $2.50 After Modest DeclineATR Stop - Newser

May 22, 2026

May 22, 2026

GALT Q1 2026 Earnings: Narrowed Loss Amid Clinical Progress, Stock RallyEPS Estimate Trend - newsline.com

May 22, 2026

May 19, 2026

Galectin Therapeutics (GALT) Q1 2026 Results Miss Estimates — EPS $-0.08 vs $-0.06Special Dividend Alert - Newser

May 19, 2026

May 18, 2026

Number of shareholders of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView

May 18, 2026

May 16, 2026

TradingKey - TradingKey

May 16, 2026

May 16, 2026

Galectin Therapeutics 1Q Research and Development Expenses $2.2M >GALT - Moomoo

May 16, 2026

May 16, 2026

Galectin Therapeutics Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart

May 16, 2026

May 15, 2026

Galectin Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 15, 2026

May 15, 2026

Is Galectin Therapeutics (GALT) Fairly Valued After Q1 2026 Earn - GuruFocus

May 15, 2026

May 15, 2026

Correct: Galectin Therapeutics 1Q Loss/Shr 8c >GALT - Moomoo

May 15, 2026

May 15, 2026

Galectin Therapeutics Reports Q1 2026 Financial Results and Advances Belapectin for MASH Cirrhosis with Positive NAVIGATE Trial Data 123 - Minichart

May 15, 2026

May 15, 2026

Galectin Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2026

May 15, 2026

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update - The Manila Times

May 15, 2026

May 15, 2026

Belapectin reduces liver stiffness in high-risk MASH cirrhosis trial - Stock Titan

May 15, 2026

May 15, 2026

Galectin Therapeutics reports Q1 2026 net loss of $5.1M, cash $14.1M; updates belapectin program - TradingView

May 15, 2026

May 15, 2026

Galectin Therapeutics 1Q 2026: Financials Not Reported — 10-Q Summary - TradingView

May 15, 2026

May 15, 2026

Galectin Therapeutics (NASDAQ: GALT) trims Q1 2026 loss as R&D falls - Stock Titan

May 15, 2026

May 15, 2026

Galectin Therapeutics (NASDAQ: GALT) narrows Q1 2026 loss but leans on large convertible debt - Stock Titan

May 15, 2026

May 15, 2026

Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

May 12, 2026

Will Galectin's New MASH Cirrhosis Data Renew Stock Momentum? - RTTNews

May 12, 2026

May 11, 2026

Galectin Therapeutics (GALT) Highlights Promising Phase 2b Trial Results - GuruFocus

May 11, 2026

May 11, 2026

Galectin Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

May 11, 2026

May 11, 2026

Galectin Therapeutics announces publication of Navigate phase 2b trial results for belapectin in the Journal of Hepatology - marketscreener.com

May 11, 2026

May 11, 2026

Galectin publishes phase 2b trial results in Hepatology - Investing.com

May 11, 2026

May 11, 2026

Galectin Therapeutics Announces Publication Of Navigate Phase 2B Trial Results For Belapectin In The Journal Of Hepatology - TradingView

May 11, 2026

May 11, 2026

Galectin publishes phase 2b trial results in Hepatology By Investing.com - Investing.com Australia

May 11, 2026

May 11, 2026

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology - Yahoo Finance

May 11, 2026

May 08, 2026

Why Galectin Therapeutics (GALT) guidance matters more than actual results | Q4 2025: Better Than ExpectedBuy Rating - newser.com

May 08, 2026

May 02, 2026

Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA - Yahoo

May 02, 2026

Apr 27, 2026

Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

Apr 27, 2026

Apr 26, 2026

Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN

Apr 26, 2026

Apr 25, 2026

GALT Price Today: Galectin Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 25, 2026

Apr 23, 2026

What are the key catalysts for Galectin Therapeutics (GALT) stock (Drifts Higher) 2026-04-23Revenue Growth Stocks - The Legal Advocate

Apr 23, 2026

Apr 22, 2026

GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment.Earnings Per Share - UBND thành phố Hải Phòng

Apr 22, 2026

Apr 22, 2026

GALT (Galectin Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares gain 3.64 percent on upbeat investor reaction.Expert Momentum Signals - UBND thành phố Hải Phòng

Apr 22, 2026

Apr 20, 2026

Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20Open Stock Signal Network - UBND thành phố Hải Phòng

Apr 20, 2026